Translating the histone code into leukemia

Journal of Cellular Biochemistry

Volumn 96, Issue 5, 2005, Pages 938-950

  Linggi, Bryan E ^a   Brandt, Stephen J ^a,b,c   Sun, Zu Wen ^a,b   Hiebert, Scott W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chromatin; Deacetylase; Histones; Leukemia; Methyltransferase

Indexed keywords

HISTONE; METHYLTRANSFERASE; PROTEIN BCL 6; TRANSCRIPTION FACTOR RUNX1;

ACETYLATION; ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL CELL; ARTICLE; CHROMOSOME TRANSLOCATION; COVALENT BOND; DROSOPHILA; GENE DISRUPTION; GENE EXPRESSION REGULATION; HISTONE CODE; LEUKEMIA; LEUKEMOGENESIS; METHYLATION; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN MODIFICATION; REGULATOR GENE; SUMOYLATION; TRANSCRIPTION REGULATION; UBIQUITINATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; CHROMATIN; CHROMOSOMES; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA-BINDING PROTEINS; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONES; HUMANS; LEUKEMIA; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; TRANSLOCATION, GENETIC;

ANIMALIA;

EID: 28044439180     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20604     Document Type: Article

References (78)

1. Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N, Downing JR, Meyers S, Hiebert SW. 2001. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 21:6470-6483.
2. Armstrong SA, Golub TR, Korsmeyer SJ. 2003. MLL-rearranged leukemias: Insights from gene expression profiling. Semin Hematol 40:268-273.
3. Ayton PM, Cleary ML. 2003. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 17:2298-2307.
4. Ayton PM, Chen EH, Cleary ML. 2004. Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein. Mol Cell Biol 24:10470-10478.
5. Baron BW, Nucifora G, McCabe N, Espinosa Rd, Le Beau MM, McKeithan TW. 1993. Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas. Proc Natl Acad Sci USA 90:5262-5266.
6. Baron BW, Stanger RR, Hume E, Sadhu A, Mick R, Kerckaert JP, Deweindt C, Bastard C, Nucifora G, Zeleznik-Le N, et al. 1995. BCL6 encodes a sequence-specific DNA-binding protein. Genes Chromosomes Cancer 13:221-224.
7. Blyth K, Cameron ER, Neil JC. 2005. The RUNX genes: Gain or loss of function in cancer. Nat Rev Cancer 5:376-387.
8. Borrow J, Stanton VP, Jr., Andresen JM, Becher R, Behm FG, Chaganti RS, Civin CI, Disteche C, Dube I, Frischauf AM, Horsman D, Mitelman F, Volinia S, Watmore AE, Housman DE. 1996. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 14:33-41.
9. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. 2004. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24:8467-8476.
10. Chevallier N, Corcoran CM, Lennon C, Hyjek E, Chadburn A, Bardwell VJ, Licht JD, Melnick A. 2004. ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. Blood 103:1454-1463.
11. Croce LD. 2005. Chromatin modifying activity of leukaemia associated fusion proteins. Hum Mol Genet 14 Spec No 1:R77-R84.
12. Daser A, Rabbitts TH. 2004. Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev 18:965-974.
13. David G, Alland L, Hong SH, Wong CW, DePinho RA, Dejean A. 1998. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 16:2549-2556.
14. David G, Turner GM, Yao Y, Protopopov A, DePinho RA. 2003. mSin3-associated protein, mSds3, is essential for pericentric heterochromatin formation and chromosome segregation in mammalian cells. Genes Dev 17:2396-2405.
15. de Bruijn MF, Speck NA. 2004. Core-binding factors in hematopoiesis and immune function. Oncogene 23:4238-4248.
16. de la Cruz X, Lois S, Sanchez-Molina S, Martinez-Balbas MA. 2005. Do protein motifs read the histone code? Bioessays 27:164-175.
17. Deguchi K, Ayton PM, Carapeti M, Kutok JL, Snyder CS, Williams IR, Cross NC, Glass CK, Cleary ML, Gilliland DG. 2003. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell 3:259-271.
18. Dhordain P, Albagli O, Lin RJ, Ansieau S, Quief S, Leutz A, Kerckaert J-P, Evans RM, Leprince D. 1997. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc Natl Acad Sci USA 94:10762-10767.
19. Dhordain P, Lin RJ, Quief S, Lantoine D, Kerckaert J-P, Evans RM, Albagli O. 1998. The LAZ3 (BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucl Acids Res 26:4645-4651.
20. DiMartino JF, Miller T, Ayton PM, Landewe T, Hess JL, Cleary ML, Shilatifard A. 2000. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood 96:3887-3893.
21. DiMartino JF, Ayton PM, Chen EH, Naftzger CC, Young BD, Cleary ML. 2002. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. Blood 99:3780-3785.
22. Dou Y, Milne TA, Tackett AJ, Smith ER, Fukuda A, Wysocka J, Allis CD, Chait BT, Hess JL, Roeder RG. 2005. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 121:873-885.
23. Durst KL, Hiebert SW. 2004. Role of RUNX family members in transcriptional repression and gene silencing. Oncogene 23:4220-4224.
24. Durst KL, Lutterbach B, Kummalue T, Friedman AD, Hiebert SW. 2003. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol Cell Biol 23:607-619.
25. Follows GA, Tagoh H, Lefevre P, Hodge D, Morgan GJ, Bonifer C. 2003. Epigenetic consequences of AML1-ETO action at the human c-FMS locus. EMBO J 22:2798-2809.
26. Gu TL, Goetz TL, Graves BJ, Speck NA. 2000. Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1). Mol Cell Biol 20:91-103.
27. Hake SB, Xiao A, Allis CD. 2004. Linking the epigenetic 'language' of covalent histone modifications to cancer. Br J Cancer 90:761-769.
28. Hess JL. 2004. MLL: A histone methyltransferase disrupted in leukemia. Trends Mol Med 10:500-507.
29. Huang S, Brandt SJ. 2000. mSin3A regulates murine erythroleukemia cell differentiation through association with the TAL1 (or SCL) transcription factor. Mol Cell Biol 20:2248-2259.
30. Huang S, Qiu Y, Stein RW, Brandt SJ. 1999. p300 functions as a transcriptional coactivator for the TAL1/SCL oncoprotein. Oncogene 18:4958-4967.
31. Huang S, Qiu Y, Shi Y, Xu Z, Brandt SJ. 2000. P/CAF-mediated acetylation regulates the function of the basic helix-loop-helix transcription factor TAL1/SCL. EMBO J 19:6792-6803.
32. Huynh KD, Bardwell VJ. 1998. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. Oncogene 17:2473-2484.
33. Huynh KD, Fischle W, Verdin E, Bardwell VJ. 2000. BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev 14:1810-1823.
34. Ichikawa M, Asai T, Saito T, Yamamoto G, Seo S, Yamazaki I, Yamagata T, Mitani K, Chiba S, Hirai H, Ogawa S, Kurokawa M. 2004. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 10:299-304.
35. Iizuka M, Smith MM. 2003. Functional consequences of histone modifications. Curr Opin Genet Dev 13:154-160.
36. Iyer NG, Ozdag H, Caldas C. 2004. p300/CBP and cancer. Oncogene 23:4225-4231.
37. Jenuwein T, Allis CD. 2001. Translating the histone code. Science 293:1074-1080.
38. Johnstone RW, Licht JD. 2003. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell 4:13-18.
39. Jones PA, Baylin SB. 2002. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428.
40. Kalkhoven E. 2004. CBP and p300: HATs for different occasions. Biochem Pharmacol 68:1145-1155.
41. Kitabayashi I, Yokoyama A, Shimizu K, Ohki M. 1998. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J 17:2994-3004.
42. Kitabayashi I, Aikawa Y, Nguyen LA, Yokoyama A, Ohki M. 2001. Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. EMBO J 20:7184-7196.
43. Klisovic MI, Maghraby EA, Parthun MR, Guimond M, Sklenar AR, Whitman SP, Chan KK, Murphy T, Anon J, Archer KJ, Rush LJ, Plass C, Grever MR, Byrd JC, Marcucci G. 2003. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 17:350-358.
44. Lachner M, O'Sullivan RJ, Jenuwein T. 2003. An epigenetic road map for histone lysine methylation. J Cell Sci 116:2117-2124.
45. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C. 2002. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21:2672-2681.
46. Larson RC, Lavenir I, Larson TA, Baer R, Warren AJ, Wadman I, Nottage K, Rabbitts TH. 1996. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J 15:1021-1027.
47. Lavau C, Du C, Thirman M, Zeleznik-Le N. 2000. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J 19:4655-4664.
48. Lemercier C, Brocard M-P, Puvion-Dutilleul F, Kao H-Y, Albagli O, Khochbin S. 2002. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J Biol Chem 277:22045-22052.
49. Liang J, Prouty L, Williams BJ, Dayton MA, Blanchard KL. 1998. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. Blood 92:2118-2122.
50. Linggi B, Muller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, Berdel WE, van der Reijden B, Quelle DE, Rowley JD, Cleveland J, Jansen JH, Pandolfi PP, Hiebert SW. 2002. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 8:743-750.
51. Marks PA, Richon VM, Miller T, Kelly WK. 2004. Histone deacetylase inhibitors. Adv Cancer Res 91:137-168.
52. Melnick A, Carlile GW, McConnell MJ, Polinger A, Hiebert SW, Licht JD. 2000. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood 96:3939-3947.
53. Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, Dou Y, Schnepp RW, Krankel C, Livolsi VA, Gibbs D, Hua X, Roeder RG, Meyerson M, Hess JL. 2005. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci USA 102:749-754.
54. O'Neil J, Shank J, Cusson N, Murre C, Kelliher M. 2004. TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 5:587-596.
55. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, Su L, Xu G, Zhang Y. 2005. hDOT1L links histone methylation to leukemogenesis. Cell 121:167-178.
56. Osada H, Grutz G, Axelson H, Forster A, Rabbitts TH. 1995. Association of erythroid transcription factors: Complexes involving the LIM protein RBTN2 and the zinc-finger protein GATA1. Proc Natl Acad Sci USA 92:9585-9589.
57. Pelletier N, Champagne N, Stifani S, Yang XJ. 2002. MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2. Oncogene 21:2729-2740.
58. Peterson CL, Laniel MA. 2004. Histones and histone modifications. Curr Biol 14:R546-R551.
59. Peterson LF, Zhang DE. 2004. The 8;21 translocation in leukemogenesis. Oncogene 23:4255-4262.
60. Plath K, Fang J, Mlynarczyk-Evans SK, Cao R, Worringer KA, Wang H, de la Cruz CC, Otte AP, Panning B, Zhang Y. 2003. Role of histone H3 lysine 27 methylation in X inactivation. Science 300:131-135.
61. Polak PE, Simone F, Kaberlein JJ, Luo RT, Thirman MJ. 2003. ELL and EAF1 are Cajal body components that are disrupted in MLL-ELL leukemia. Mol Biol Cell 14:1517-1528.
62. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. 2000. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13:199-212.
63. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA. 2004. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:941-953.
64. Sinclair DA, Ruddell AA, Brock JK, Clegg NJ, Lloyd VK, Grigliatti TA. 1992. A cytogenetic and genetic characterization of a group of closely linked second chromosome mutations that suppress position-effect variegation in Drosophila melanogaster. Genetics 130:333-344.
65. Smith ST, Petruk S, Sedkov Y, Cho E, Tillib S, Canaani E, Mazo A. 2004. Modulation of heat shock gene expression by the TAC1 chromatin-modifying complex. Nat Cell Biol 6:162-167.
66. So CW, Cleary ML. 2004. Dimerization: A versatile switch for oncogenesis. Blood 104:919-922.
67. Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, Housman D, Doggett NA, Rowley JD, Zeleznik-Le NJ. 1997. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci USA 94:8732-8737.
68. Spotswood HT, Turner BM. 2002. An increasingly complex code. J Clin Invest 110:577-582.
69. Strahl BD, Allis CD. 2000. The language of covalent histone modifications. Nature 403:41-45.
70. Tenney K, Shilatifard A. 2005. A COMPASS in the voyage of defining the role of trithorax/MLL-containing complexes: Linking leukemogensis to covalent modifications of chromatin. J Cell Biochem 95:429-436.
71. Turner BM. 2000. Histone acetylation and an epigenetic code. Bioessays 22:836-845.
72. Turner BM. 2002. Cellular memory and the histone code. Cell 111:285-291.
73. Turner BM. 2005. Reading signals on the nucleosome with a new nomenclature for modified histones. Nat Struct Mol Biol 12:110-112.
74. Wong C-W, Privalsky ML. 1998. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARα, and BCL-6. J Biol Chem 273:27695-27702.
75. Wysocka J, Swigut T, Milne TA, Dou Y, Zhang X, Burlingame AL, Roeder RG, Brivanlou AH, Allis CD. 2005. WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell 121:859-872.
76. Yamaguchi Y, Imai Y, Izutsu K, Asai T, Ichikawa M, Yamamoto G, Nitta E, Yamagata T, Sasaki K, Mitani K, Ogawa S, Chiba S, Hirai H, Kurokawa M. 2004. AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. J Biol Chem 279:15630-15638.
77. Yang G, Khalaf W, van de Locht L, Jansen JH, Gao M, Thompson MA, van der Reijden BA, Gutmann DH, Delwel R, Clapp DW, Hiebert SW. 2005. Transcriptional repression of the neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein. Mol Cell Biol 25:5869-5879.
78. Yokoyama A, Wang Z, Wysocka J, Sanyal M, Aufiero DJ, Kitabayashi I, Herr W, Cleary ML. 2004. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol 24:5639-5649.